UNSPSC 51361926: Barbital or barbitone

This classification denotes a barbiturate with the molecular formula C8H12N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5WZ53ENE2P, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5,5-diethyl- (9ci) but generally known as barbital, which bears US NIH Compound Identifier 2294. Barbital most often comes in base, n-glucoside, and sodium forms. European Medicines Agency schedules Barbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06102MIG.

UNSPSC 51361926 Barbital or barbitone is a Commodity code nominally covering barbiturate pharmaceutical products, but the three most recent state and local solicitations tied to this code show minimal alignment with barbiturate procurement and instead reflect broader pharmaceutical supply, naloxone distribution, and generic drug programs. The actual recent buying activity under this code spans naloxone and drug deactivation systems (community health support), direct-to-manufacturer prescription program infrastructure (state health agency), and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances that aggregate demand across multiple jurisdictions and states.

Recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (due July 26, 2023), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (closed April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products open to multiple participating states including Oregon with proposals due March 26, 2026. The geographic spread reflects activity across Florida, Texas, Minnesota, and Oregon, with cooperative purchasing structures extending the reach of individual state procurements. The code shows limited targeted barbiturate activity; vendors pursuing this code should anticipate broader pharmaceutical distribution, generic drug sourcing, and public health supply chains rather than controlled-substance-specific procurement.